Highest-materiality recent filing
Biomerica sells Diagnosis stake for $500k to CEO-affiliated buyers; note forgivable on transfer
Biomerica sells its 6% stake in Diagnosis S.A. (78,750 shares) to CEO-affiliated entities for $500,000.
Biomerica receives Nasdaq bid price deficiency notice; enters $5.5M at-market stock offering
Nasdaq notified Biomerica on May 7, 2024 that bid price was below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).
Biomerica submits final H. pylori dataset to FDA for 510(k) review of hp+detect test
Submitted final H. pylori data-set to FDA on Sep 15, 2023, as requested during FDA's 510(k) review.
Biomerica closes $8M public offering of 3.33M shares at $2.40/share
Raised $8M gross, ~$7.4M net from 3,333,333 shares at $2.40/share via Craig-Hallum.
Subject Global Assessment of Relief (SGA) endpoint achieved p=0.007 for all IBS subtypes at 8 weeks.
Biomerica preliminary Q2 revenue $4.6M (+238% YoY); backlog $4M; InFoods trial data due Jan 2022
Revenue approximately $4.6M for Q2 ended Nov 30, 2021, up 238% from $1.4M a year ago, driven by COVID test demand.
SEC concludes investigations into Biomerica and CEO with no enforcement action
SEC notified Biomerica on Dec 2, 2021 that subpoena investigations from July & Dec 2020 are closed with no enforcement action.
Biomerica restates FY2021 & earlier results due to stock-based compensation accounting errors
Non-cash stock-based compensation was understated; expensed on vesting dates instead of ratably over vesting period, with incorrect forfeiture estimates.
On the same date, the Board appointed Mr. Eric Chin to serve as an independent member of the Board, effective immediately
Effective June 4, 2025, Ms. Cathy Coste stepped down as a member of the Board of Directors
On June 26, 2024, Mr. Jack Kenny notified Biomerica, Inc. (the "Company") of his resignation as a member of the board of directors of the Company (the "Board") and all committees thereof, and as the Company’s Chairman of the Board, effective immediately.
Effective August 25, 2023, the board of directors (the “Board”) of Biomerica, Inc. (the “Company”) expanded the size of the Board by one member and elected and appointed Mr. Jack Kenny to serve as an independent member of the Board effective immediately.
Effective March 1, 2023, the Board of Directors of Biomerica, Inc. (the “Company”) appointed Gary Lu as its Chief Financial Officer, principal financial officer and principal accounting officer.
In connection with Mr. Lu’s appointment as Chief Financial Officer, Steve Sloan, the Company’s former Chief Financial Officer and current interim Chief Financial Officer, stepped down as interim Chief Financial Officer, effective as of March 1, 2023.
On December 12, 2022, Steve Sloan notified Biomerica Inc. (the “Company”) that he will be stepping down from his position as Chief Financial Officer (“CFO”) of the Company.
At the Annual Shareholder Meeting, shareholders elected Mr. David Moatazedi to fill the seat vacated by Mr. Sirgo.
On December 7, 2022, at the Company’s Annual Shareholder Meeting, Mr. Mark Sirgo stepped down as a member of the Board of Directors of Biomerica.
Max materiality 0.80 · Median 0.50 · Most common event other_material